BEAMTREE HOLDINGS LIMITED (BMT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BMT

BMT - BEAMTREE HOLDINGS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -2.61
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.28

19 Jun
2025

-0.005

OPEN

$0.28

-1.75%

HIGH

$0.29

849,191

LOW

$0.28

TARGET
$0.70 150.0% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . DOC . EBO . HLS . IDX . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL . SLA .
FNARENA'S MARKET CONSENSUS FORECASTS
BMT: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 1.8 - 1.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-1.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx27.6 M
Book Value Per Share xxxxxxxxxxxxxxx16.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-0.5 M
Net Profit Margin xxxxxxxxxxxxxxx-18.50 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-10.82 %
Return on Invested Capital xxxxxxxxxxxxxxx-10.60 %
Return on Assets xxxxxxxxxxxxxxx-8.36 %
Return on Equity xxxxxxxxxxxxxxx-10.82 %
Return on Total Capital xxxxxxxxxxxxxxx-12.56 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-0.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx31 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx5 M
Price To Book Value xxxxxxxxxxxxxxx1.41

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx4.0 M
Capex % of Sales xxxxxxxxxxxxxxx14.57 %
Cost of Goods Sold xxxxxxxxxxxxxxx29 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx4 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Shaw and Partners

20/02/2025

1

Buy

$0.70

150.00%

Beamtree Holdings provided a first half EBITDA outcome that was better than Shaw and Partners forecast. FY25 annual recurring revenue has been pushed out  with the company reducing guidance for FY25 to growth of 10% versus 20% previously.

Shaw and Partners still expects a strong second half and assesses the outlook into FY26 is well supported, with plenty of catalysts. The Buy, High risk rating is reiterated and the target is steady at 70c.

FORECAST
Shaw and Partners forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.20 cents.
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.10 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Petra Capital

12/06/2025

1

Buy

$0.50

78.57%

Beamtree Holdings has secured a five-year partnership with the UK NHS Confederation, observes Petra Capital.

This launches the Evolve Collaborative, a strategic partnership between Australian health technology company Beamtree and the UK’s NHS Confederation to deploy predictive analytics and benchmarking tools to up to 120 hospital trusts.

The broker notes initial pricing is GBP50,000 per trust, with rollout from late-2025 and full implementation by January 2026, offering upside risk to FY27 revenue forecasts if uptake is strong.

While no changes have been made to the analyst's earnings forecasts, Petra sees the opportunity as highly strategic. Potential downstream benefits are noted for Beamtree’s suite of hospital coding tools including PICQ and autonomous coding.

Petra Capital retains a Buy rating and 50c target price.

FORECAST
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.40 cents.
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.30 cents.
Access Extra Coverage Research History >

BMT STOCK CHART

FNArena News on BMT

Latest Healthcare services News

1
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
2
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
3
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals
4
Funding Overhang Weighs On Ramsay’s Rebound

Jun 10 2021 - Australia
5
Treasure Chest: More Pfizer Growth For Ebos Group

May 24 2021 - Treasure Chest
6
Treasure Chest: Demand Pumps Ramsay Health

Mar 03 2021 - Treasure Chest
7
Healius Enjoying Testing Times

Dec 11 2020 - Australia
8
The First Connection

Dec 10 2020 - Weekly Reports
9
Subdued Recovery For Ramsay Health Care

Nov 16 2020 - Australia
10
Recovery Underway For Sonic Healthcare

Jun 25 2020 - Australia